Core Laboratories (NYSE:CLB) Announces Q4 2026 Earnings Guidance

Core Laboratories (NYSE:CLB) issued an update on its fourth quarter 2026 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 0.120-0.200 for the period, compared to the consensus EPS estimate of 0.190. The company issued revenue guidance of $128.5 million-$134.5 million, compared to the consensus revenue estimate of $134.2 million.

Core Laboratories Trading Up 2.3%

NYSE:CLB opened at $10.64 on Friday. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.19 and a quick ratio of 1.55. Core Laboratories has a one year low of $9.13 and a one year high of $20.36. The firm has a 50-day moving average of $11.00 and a 200-day moving average of $13.92. The company has a market cap of $488.16 million, a PE ratio of 28.00, a PEG ratio of 2.12 and a beta of 1.14.

Core Laboratories (NYSE:CLB) last released its quarterly earnings data on Wednesday, October 28th. The oil and gas company reported $0.16 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.16. The business had revenue of $132.08 million for the quarter, compared to analysts’ expectations of $131.87 million. Core Laboratories had a return on equity of 8.94% and a net margin of 3.42%. The firm’s quarterly revenue was down 1.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.22 EPS. As a group, equities research analysts expect that Core Laboratories will post 0.56 EPS for the current fiscal year.

Core Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 30th. Investors of record on Monday, November 9th will be given a dividend of $0.01 per share. This represents a $0.04 annualized dividend and a yield of 0.4%. The ex-dividend date is Monday, November 9th. Core Laboratories’s dividend payout ratio (DPR) is presently 10.53%.

Analyst Ratings Changes

A number of research analysts have issued reports on CLB shares. Johnson Rice raised shares of Core Laboratories from a “hold” rating to a “buy” rating and set a $21.00 target price for the company in a report on Thursday, August 13th. Wall Street Zen raised Core Laboratories from a “sell” rating to a “hold” rating in a research report on Saturday, August 1st. Finally, Weiss Ratings upgraded shares of Core Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday. One equities research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $21.00.

More Core Laboratories News

Here are the key news stories impacting Core Laboratories this week:

• Positive Sentiment: Third-quarter revenue increased 6% sequentially to $132.1 million, while adjusted EPS rose 46% sequentially to $0.16. The company also repurchased 87,873 shares for approximately $1.1 million and maintained its quarterly dividend at $0.01 per share. Core Lab Reports Third Quarter 2026 Results
• Neutral Sentiment: Management’s fourth-quarter outlook calls for revenue of $128.5 million to $134.5 million and EPS of $0.12 to $0.20. The midpoint implies a sequential revenue decline but leaves room for results near the current consensus range. The board also approved a $0.01-per-share dividend payable November 30 to shareholders of record November 9. Core Laboratories Provides Fourth-Quarter Guidance
• Negative Sentiment: Although adjusted EPS of $0.16 was in line with some analyst estimates, it was below the $0.17 Zacks consensus and down from $0.22 a year earlier. GAAP EPS was $0.12, net income fell sharply year over year, and revenue declined 2% from the prior-year quarter. Core Laboratories Q3 Earnings Miss Estimates
• Negative Sentiment: Margins remain the main concern: adjusted operating income rose sequentially but fell 24% year over year, while free cash flow was only $1.7 million. Fourth-quarter revenue guidance has a midpoint slightly below consensus, and the EPS range includes $0.12—well below the $0.19 consensus estimate—reinforcing investor concerns about near-term earnings momentum.

About Core Laboratories

Core Laboratories N.V. (NYSE: CLB) is a global provider of proprietary reservoir description and production enhancement services and products for the energy industry. The company helps oil and natural gas producers evaluate reservoirs, improve well performance, and optimize the recovery of hydrocarbons.

Its reservoir description activities include geological and geochemical analysis, petrophysical services, core and fluid analysis, and laboratory testing used to characterize subsurface formations.